Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
Related Articles
Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-Thalassemia
Tisagenlecleucel Demonstrates Real-World Clinical Benefit in DLBCL
Navitoclax Overcomes Ruxolitinib Resistance for Myelofibrosis
Related Videos
Dr. Zain on Targets Under Investigation in T-Cell Lymphomas
Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice
Dr. Babushok on Treatment Advances in Paroxysmal Nocturnal Hemoglobinuria
News >

Ixazomib Phase III Trial Discontinued in AL Amyloidosis

Gina Columbus @ginacolumbusonc
Published: Thursday, Jun 06, 2019

Phil Rowlands, PhD

Phil Rowlands, PhD

Ixazomib (Ninlaro) in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared with standard therapy in patients with relapsed/refractory systemic light-chain (AL) amyloidosis, missing one of two primary endpoints in the phase III TOURMALINE-AL1 trial and leading to discontinuation of the study.1

Ixazomib is currently approved by the FDA in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received ≥1 prior therapy.

References

  1. Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis. Takeda Pharmaceutical Company. Published June 5, 2019. https://bit.ly/2Xu2CIX. Accessed June 5, 2019.
  2. Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605. doi: 10.1182/blood-2017-03-771220.

... to read the full story
To Read the Full Story
REGISTER
LOG IN

View Other News on Hematologic Oncology
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
 
x